Loading
Prostate Cancer Treatment and Research / Cancer Diagnosis and Treatment · Journal article
Iju Case Reports · August 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a case report of a 72-year-old man with therapy-induced neuroendocrine prostate cancer metastatic to the urethra who was treated with platinum-based chemotherapy and external-beam radiotherapy and achieved durable local control for 2 years 10 months before distant progression. The report suggests this combined modality approach may be worth considering for this exceptionally rare and aggressive condition, but the evidence is limited to a single patient outcome.
Case report. 72-year-old man with 14-year history of prostate adenocarcinoma on androgen deprivation therapy presenting with hematuria and dysuria.. Intervention: Platinum-based chemotherapy with external-beam radiotherapy.
Urethral metastasis of therapy-induced neuroendocrine prostate cancer achieved durable local control with platinum-based chemoradiotherapy Patient survived 2 years 10 months from presentation with later distant progression Histology showed high-grade adenocarcinoma with small cell carcinoma component, positive for synaptophysin and prostate-specific antigen
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case suggests platinum-based chemoradiotherapy may warrant consideration for urethral metastasis from therapy-induced neuroendocrine prostate cancer, a condition with limited treatment options. However, conclusions from a single case are hypothesis-generating only and cannot guide practice without confirmation from larger series or trials.
A single case report of an exceptionally rare presentation (urethral metastasis of therapy-induced neuroendocrine prostate cancer) treated with chemoradiotherapy, describing outcome in one patient without comparator or control group.
As stated by the source record.
Quoted from the source exactly as published.
This case suggests platinum-based chemoradiotherapy may warrant consideration for urethral metastasis from therapy-induced neuroendocrine prostate cancer, a condition with limited treatment options. However, conclusions from a single case are hypothesis-generating only and cannot guide practice without confirmation from larger series or trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction: Urethral metastasis of prostate cancer is exceptionally rare, particularly in castration-resistant disease. Therapy-induced neuroendocrine prostate cancer (t-NEPC) is an aggressive variant with limited treatment options. Case Presentation: A 72-year-old man, 14 years after diagnosis of prostate adenocarcinoma treated with androgen deprivation therapy, presented with hematuria and dysuria. Prostate-specific antigen was 2.05 ng/mL and neuron-specific enolase was 28.0 ng/mL. Urethroscopy revealed papillary tumors in the pendulous urethra. Histology showed high-grade adenocarcinoma with a small cell carcinoma component, positive for synaptophysin and prostate-specific antigen. Genomic profiling demonstrated PTEN loss, TP53 mutation, and androgen receptor amplification. Platinum-based chemotherapy with external-beam radiotherapy achieved durable urethral local control despite later distant progression; the patient survived 2 years 10 months. Conclusion: Platinum-based chemoradiotherapy may provide durable local control of urethral metastasis from t-NEPC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.